Header links
Intranet
Donate now
image/svg+xml Map
Contact us

Elisabet Megías Roda

Elisabet Megías Roda

-

Institutions of which they are part

Administration and Management
Protein kinases in cancer research
Vall Hebron Institut de Recerca
Elisabet Megías Roda

Elisabet Megías Roda

Elisabet Megías Roda

Institutions of which they are part

Administration and Management
Protein kinases in cancer research
Vall Hebron Institut de Recerca

-

-

Projects

Grup de Recerca Emergent (GRE) Childood Cancer & Blood disorders

IP: Lucas Moreno Martín-Retortillo
Collaborators: Luís Gros Subias, Raquel Andreu Vilarroig, Andrea Vilaplana Blanes, Pablo Velasco Puyó, Laura Murillo Sanjuán, Maria Isabel Benitez Carabante, Aroa Soriano Fernández, Guillem Pons Barcons, Jose Miguel Lizcano De Vega, Maria Cristina Díaz de Heredia Rubio, Maria Luz Uría Oficialdegui, Maria Jose Pérez García, Miguel Segura Ginard, M Mar Mañu Pereira, Lorena Valero Arrese, Thaïs Murciano Carrillo, Constantino Sábado Álvarez, Anna Llort Sales, Elisabet Megías Roda, Raquel Hladun Alvaro, Carlota Aguilera Ordoñez, Adria Molero Valenzuela, Júlia Sansa Girona, Gabriela Guillén Burrieza, Laura Alonso Garcia, Victoria Gutierrez Valle, Idoia Bolinaga Ayala, Josep Roma Castanyer, Sergio Espinosa Gil, Elena Andretta, Claire Diot, Amira Idrizovic
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00638
Duration: 01/01/2022 - 30/06/2025

Related news

Laboratori de Sarcomes Infantils

VHIR drives cancer research with new personalized therapies and advances in biomarkers

On World Cancer Research Day, we highlight research aimed at improving treatments for both pediatric and adult cancers through innovative techniques.

Laboratori de Sarcomes Infantils

New therapeutic target for an aggressive childhood cancer affecting the muscles

The research team has shown that inhibiting the TRIB3 protein slows the growth of rhabdomyosarcoma and improves survival in animal models.

Dr. José Miguel Lizcano i Dr. Sergio Espinosa

Study identifies strategy to avoid resistance to cancer therapy

A team from Vall d'Hebron Research Institute (VHIR) and the Autonomous University of Barcelona (UAB) highlights the ERK5 protein as a key factor in the resistance to cancer drugs.

See more

Related professionals

Sara Albarral Perez

Sara Albarral Perez

Administrative
Purchase and Biddings Unit
Finance Directorate
Read more
Lucía Rodriguez Diez

Lucía Rodriguez Diez

Predoctoral researcher
Rheumatology
Read more
Amparo García Burillo

Amparo García Burillo

Molecular Medical Imaging
Read more
Anna Jeanne Behr

Anna Jeanne Behr

Predoctoral researcher
Gene Therapy at Nervous System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.